Incyte Corp (NAS:INCY)
$ 57.05 -0.55 (-0.95%) Market Cap: 12.83 Bil Enterprise Value: 9.14 Bil PE Ratio: 17.29 PB Ratio: 2.38 GF Score: 88/100

Incyte Corporation - Pemazyre FDA Approval Transcript

Apr 20, 2020 / 12:00PM GMT
Release Date Price: $101.19 (+1.19%)
Operator

Greetings. And welcome to the Pemazyre FDA approval conference call. (Operator Instructions) As a reminder, this conference is being recorded.

It's now my pleasure to introduce your host, Mike Booth, Head of Investor Relations for Incyte. Please go ahead, Mike.

Michael Booth
Incyte Corporation - Divisional VP of IR & Corporate Social Responsibility

Thank you, Kevin. Good morning. And welcome to our conference call and webcast to discuss the FDA approval of Pemazyre, which was announced late Friday. I'm joined on the call today by Hervé, Steven and Barry, who will deliver our prepared remarks; and by Christiana, who will participate in the Q&A session.

(Operator Instructions) I also ask that we seek to split the Q&A session, first, asking questions related to Pemazyre and cholangiocarcinoma; and towards the end of the hour, transitioning to any COVID-19 topics that you might wish to raise.

Before we begin, I must remind you that safe harbor rules govern our remarks today and any forward-looking statements that we may

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot